MOLECULAR PARTNERS AG (MOLN) News
Filter MOLN News Items
MOLN News Results
|Loading, please wait...|
MOLN News Highlights
- For MOLN, its 30 day story count is now at 4.
- Over the past 14 days, the trend for MOLN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- AG, DRUG and NVS are the most mentioned tickers in articles about MOLN.
Latest MOLN News From Around the Web
Below are the latest news stories about Molecular Partners Ag that investors may wish to consider to help them evaluate MOLN as an investment opportunity.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in the SVB Leerink 11th Annual Global Healthcare Conference 2022. The presentation will take place on Wednesday, February 16, at 9:20 am ET. The webcasted prese
Molecular Partners AG (NASDAQ: MOLN) and its partner Novartis AG (NYSE: NVS), have requested FDA Emergency Use Authorization (EUA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19. This submission is based on the totality of the data from clinical and preclinical studies, including the results of the Phase 2 portion of the EMPATHY study, which enrolled 407 symptomatic COVID-19 patients. Related: Novartis To In-License COVID-19 Treatment From Molecular Partners, After Enc
Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of COVID-19
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, was informed by its partner Novartis that the company has requested Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for ensovibep, a DARPin antiviral therapeutic candidate
It's hard for any stock to deliver positive gains while the market is falling. Molecular Partners' (NASDAQ: MOLN) shares have skyrocketed more than 40% year to date. On Jan. 10, Molecular Partners and Novartis announced positive results from their Empathy phase 2 study of ensovibep in treating acute COVID-19 patients.
Novartis and Molecular Partners reported positive results for COVID-19 candidate ensovibep.
I hope you enjoyed the long weekend, but it's time to get back into investing with the biggest pre-market stock movers for Tuesday!
Agreement grants global rights of ensovibep to Novartis, who will lead further development and commercialization of the programFinancial terms include milestone payment of CHF150 million to Molecular Partners and 22% royalty on ensovibep sales in relevant territoriesCollaboration will focus on rapidly progressing ensovibep’s availability to COVID-19 patients via expedited regulatory processes ZURICH-SCHLIEREN, Switzerland & CONCORD, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pu
Happy Friday, trader!
BVF Partners L.P. acquired shares from Essex Woodlands Health Ventures FundsZURICH-SCHLIEREN, Switzerland & CONCORD, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today reported changes in ownership based on disclosure notifications received according to Article 120 of the Swiss Financial Market
Regulatory and other pipeline updates from Biogen (BIIB) and AMGN are among a few key highlights from the biotech sector during the past week.